Ksenia Nazmieva

Dr. Ksenia Nazmieva

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2022 in Problems of Endocrinology
Verified
Journal Article
Open access
PDF file
ККК. О. Кузнецов
К. О. Кузнецов
ЭСЭ. Р. Сафина
Э. Р. Сафина
ДГД. В. Гаймакова
Д. В. Гаймакова
ЯФЯ. С. Фролова
Я. С. Фролова
ИОИ. Ю. Оганесян
И. Ю. Оганесян
ЭРЭ. В. Ризванова
Э. В. Ризванова
Metformin is a first-line antidiabetic drug for the treatment of type 2 diabetes mellitus (DM2); its molecular target is AMP-activated protein kinase (AMPK), which is involved in many metabolic processes. Metformin not only reduces blood glucose levels and improves insulin sensitivity, but also inhibits lipolysis and reduces cardiovascular risk in patients with DM2. In recent years, it has been proven that metformin slows down the aging process, stimulates hair growth, eliminates cognitive impairment, and also has an antitumor effect. Most basic studies have shown that metformin inhibits the growth of tumor cells and promotes cellular apoptosis, while clinical studies show contradictory results. This discrepancy can be explained by the difference in the concentration of metformin between basic and clinical studies. The maximum daily dose of metformin for patients with DM2 is 2500 mg / day, and the dose used in basic research was much higher. Metformin directly activates the AMPK signaling pathway, inhibits the production of reactive oxygen species, induces the activation of mTORC1, inhibits cyclin D1, which leads to a reduction in the risk of the occurrence and development of malignant neoplasms. In addition, metformin indirectly inhibits tumor growth, proliferation, invasion and metastasis by reducing the concentration of glucose in the blood, insulin resistance, as well as by reducing inflammation and affecting the tumor microenvironment. Glycolysis plays an important role in the energy metabolism of tumors, and metformin is able to have an inhibitory effect on it. Currently, studies of the mechanism of antitumor effects of metformin are becoming more extensive and in-depth, but there are still some contradictions.

22 November 2024 in Obstetrics, Gynecology and Reproduction
Verified
Journal Article
Open access
PDF file
IZI. A. Zhirnov
I. A. Zhirnov
KNKsenia Nazmieva
Ksenia Nazmieva
AKA. I. Khabibullina
A. I. Khabibullina
LIL. A. Ilyasova
L. A. Ilyasova
NSN. S. Saidmursalova
N. S. Saidmursalova
UGU. U. Galimova
U. U. Galimova
Introduction. The environment undoubtedly affects the physiological processes in human body, which may be both beneficial and harmful. From 2011 to 2021, the incidence of female infertility in Russia increased by 30 % reaching 789.1 cases per 100,000 women in 2021.Aim: to assess an impact of environmental factors including endocrine disrupting chemicals (EDC) on women's reproductive health by assessing available publications.Materials and Methods. Available studies were searched through the scientific literature databases until April 2024 by revealing 5,732 articles in the PubMed/MEDLINE database, 6,587 in Google Scholar and 2,350 in eLibrary. The publications were selected in accordance with PRISMA recommendations. The current review included 90 publications.Results. Fertility experimental and epidemiological studies showed that environmental factors such as climate, temperature, seasonality, radiation, air pollution, diet and energy balance, working environment, bad habits (e.g. smoking), EDC (plasticizers, heavy metals, parabens, pesticides, industrial chemicals and their by-products, medicines, perfluorochemicals, antibacterial agents) may be associated with impaired female reproductive function.Conclusion. Environmental factors, including EDC, have a significant impact on women's reproductive health and can negatively affect fertility. The main findings of current research confirm a need to raise awareness of the risks associated with exposure to chemicals on women's body.

1 November 2025 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
SASabina Abdullaeva
Sabina Abdullaeva
PAPolina Abdullaeva
Polina Abdullaeva
RGRenata Gabdrahimova
Renata Gabdrahimova
KNKsenia Nazmieva
Ksenia Nazmieva
Margarita NeganovaMargarita Neganova
Margarita Neganova
VCVladimir N. Chubarev
Vladimir N. Chubarev
Background: Hormone signaling plays a significant role in cancerogenesis. This review presents a comprehensive analysis of FDA-approved drugs, as well as recent clinical trials of drugs acting on hormone signaling pathways. It discusses traditional methods of hormonal cancer therapy and identifies new mechanisms in cancer hormonal signaling. The review has made use of the databases Clinicaltrials.gov and PubMed to find new trends in the development of anti-cancer drugs and related hormonal-dependent mechanisms of breast cancer. Methods: A search of the Drugs@FDA database was conducted to identify pharmaceutical agents approved by the FDA for the treatment of hormone-dependent breast tumors. The clinical trials for these drugs were obtained from ClinicalTrials.gov. The search was expanded from 2018 to early 2024. The keywords used in the search for information were breast cancer, hormonal signaling pathways, luminal types of breast cancer, and hormone-dependent breast cancer. The drug targets, pharmacological information, and clinical data were obtained from the PubMed database. Results: An analysis of the ClinicalTrials.gov database revealed that the pharmacokinetic direction has significant potential for the discovery of new drugs. The metabolites of SERMs metabolites and their combination have the potential to enhance the efficiency of prodrug. Small molecules can penetrate through the blood-brain-barrier, making them a promising avenue for treating brain metastasis. New SERDs, such as ZB716, exhibit superior oral bioavailability compared to fulvestrant, which is solely administered via injection. The investigation of the signaling hormonal pathways of BC allows for the enhancement of personalised anti-cancer therapy and the overcoming of resistance. Consequently, the specific mechanism of action of ARV-471 (the PROTAC group) enhances sensitivity to drug-resistant targets and affects non-enzymatic functions. Furthermore, PROTACs exhibit markedly enhanced target selectivity in comparison to traditional inhibitors. The combination of endocrine therapy for breast cancer with compounds that target mTOR, PI3K, CDK4/6, and other pathways holds considerable promise. The combination of letrozole with everolimus demonstrated the most promising outcome, with a median progression-free survival period of 22 months, a significant improvement over the 9-month median progression-free survival observed in monotherapy with letrozole. Conclusion: It is evident that traditional endocrine treatments play a pivotal role in the management of HR+ BC. However, the emergence of resistance necessitates the development of novel therapeutic strategies. These strategies should be based on pharmacokinetics, further investigation of the molecular signaling pathways of BC, such as new SERMs, SERDs, PROTACs, as well as new drug groups, like SERCAs, CERANs, SHERPAs. Combination therapy represents the most promising avenue for BC treatment. While PROTAC combination with new monotherapeutic agents for BC treatment has yet to be investigated, we believe that such combinations have the potential to make the treatment more selective, effective, and personalised in the future.

8 October 2024 in Molecules
Verified
Journal Article
Open access
PDF file
AMArina Murashkina
Arina Murashkina
ABAndrei V. Bogdanov
Andrei V. Bogdanov
AVAlexandra Voloshina
Alexandra Voloshina
ALAnna Lyubina
Anna Lyubina
ASAleksandr Samorodov
Aleksandr Samorodov
IKIrina D. Krylova
Irina D. Krylova
An approach to the synthesis of phosphoryl substituted spiro-1,3-dioxolane oxindoles was developed from the base-catalyzed reaction of various isatins with (3-hydroxyprop-1-yn-1-yl)phosphonates. It was found that various aryl-substituted and N-functionalized isatins with the formation of appropriate products with high yields and stereoselectivity when using t-BuOLi are able to react. Cytotoxic activity evaluation suggests that the most significant results in relation to the HuTu 80 cell line were shown by N-benzylated spirodioxolanes. 5-Cloro-N-unsubstituted spirooxindoles exhibit antiaggregational activity exceeding the values of acetylsalicylic acid.

30 June 2023 in Creative surgery and oncology
Verified
Journal Article
Open access
PDF file
SKSh. R. Kzyrgalin
Sh. R. Kzyrgalin
RYR. S. Yamidanov
R. S. Yamidanov
KNKsenia Nazmieva
Ksenia Nazmieva
SGSh. Kh. Gantsev
Sh. Kh. Gantsev
Cancer is one of the most common diseases in the world. Th e transcription factor NF-κB plays a key role in various physiological processes including immune response, cell proliferation, cell apoptosis and inflammation. Due to participation of NF-kappa B signaling pathways in carcinogenesis, angiogenesis, and tumor resistance to chemo- and radiotherapy, the factor is considered to be the ideal target for pharmacological treatment of cancer. Th e paper presents a literature review of the RSCI, PubMed, Scopus, Web of Science, Chemical Abstracts NCCN databases and other open access data. The carcinogenesis inhibitors were selected from all NF-κB inhibitors found. Inhibitors with antitumor activity of analytical interest include Bruton tyrosine kinase (BTK) inhibitors, cellular inhibitors of apoptosis proteins (c-IAP), proteasome inhibitors, and one inhibitor of NF-κB translocation to the nucleus. Th e authors analyzed products of diff erent development stages with recorded antitumor activity to varying degrees. NF-κB inhibitors are promising drug candidates, but since NF-κB is involved in most biological processes and the broad spectrum of action can cause side eff ects, the selective action of these compounds is to be explored.